Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buyout news coming?
AMBS has developped their product pipeline, so the products are worth much more each when partnered or sold. That gives a significant plus in shareholder value. You should be patient, this will go to $45/share in the future (without RS), like Avxl went from.17 to $1/share ++
Share price is significantly oversold! This stock should have a market cap of +$400 million instead of +$4 million
For honest comments: read the sticky posts!
What just happened to the share price?
In the week of Jan 11th.There is a BIO conference that runs parallel to the JPM conference. Announcing a deal during that time is probably a good idea as there will be a lot of investors looking for news. They won't care where it came from as long as there is some news.
I agree:sold or partnered.I'm very bullish.
AVXL had a PT of $7/share rated by Maxim when it was worth .17 dollar/share. And guess what? They were right!! AMBS has a much bigger pipeline so a PT of $45/share is not too far fetched.
Do you really think you can influence my point of view? $45/share PT according to SeeThruEquity
Sold,spinned off or partnered,with significant milestone payments. The advantage of such an experienced BOD is that they will have a very well negotiated partnership.
If they do a spin off,we will get shares from the spin off company as a sort of dividend.
False information!The company will develop or Eltro or ESS till one of them gets commercialized. Afterwarts they will develop the other drug. Cash burn now is only $500k/month and partnerships are coming. I am very happy with the blog.
Hear why Dr. David Ahrenholz says there is currently a great need for ESS: https://t.co/hjVgJsJzry $AMBS
The diagnostic division is worth +$300M. Well negotiated Partnerships will come. Please stop crying, because this baby is going to $4/share again soon.
So they can only issue a small part from AS to OS. You know why the company wants to rise the number of AS?! To avoid a hostile takeover. When you see that an analyst firm gives ambs a price target of $45 and reaffirmed that yesterday, you don't want your company to be sold for 50 cents or 1 dollar, do you?
Johnson&Johnson will partner for Parkinson and probably Man-F. It is a publicly known secret. It is more like when than if IMO.
I agree.It's good he wants to be compensated in common shares, that shows his faith in the company.
Next PR will make the SP explode. It will be about partnership, or the spin off from the diagnostic division. IMO
Todays' note of effectiveness is a good sign.
Partnership too - milestone payment.
19million OS after the conversion. Their diagnostic division on its' own is already valued around +300 million dollar. That is $15/share. Add the therapeutic division to that and you still have a goldmine.
After the conversion is finished the company will have 19million shares outstanding. I can live with that, I thought it would be much worse, but now I studied the files much more profound. Now they need partnerships and the share price will be above the dollar again.
Nobody is interested in the diagnostic division and it takes one year before there are any phase 2 results from the therapeutic division. Fact! Another fact there is dilution and the company has no money for a long time, so they will have to dilute again. No way AMBS will be listed on Nasdaq the first 5 years unless they can raise at least $60 million so they can fund operations for at least 18 months and execute another reverse split.
After the conversion is finished,he will raise capital by diluting the authorised into outstanding shares by At The Market trading. After that is finished the share price will be around .01-.05 and then he will do anothe 1/150 reverse split. Then is the time to buy. But for now stay away from buying.
To those who want to get in now: what do you think the share price will do the next trading day, knowing there is dilution and the share price is down more than 15%?
The company is a "buy" when:
1. they've sufficient financial resources to fund operations for at least 18 months AND
2. when there is a significant milestone (phase 2b results) in reach before the financial resources are gone
This is not the case. On the contrary, the company is almost out of cash and heading to BK if they cannot find a partner soon/do the spin off between therapeutic/diagnistic division.
Share price by next Friday?0,20dollar/share?
'The CEO never wanted uplisting, just needed a higher share price for dilution
And everybody is a bagholder now. He tricked us. If he really wanted an uplisting, he would have uplisted when the share price was $4-6/share. Now the share price will keep coming down? Why? Because the company stil hasn't any financial resources. The company needs a very big dilution, if there are an interested parties, to get at least $60 million dollar so they will have sufficient cash to continue operation for at least 18 months. Oh yes, there will be another reverse split.' From annickawaechter at yahoofinance
It says perfectly what I am thinking. Unless a miracle happens this will go to below .01/share. Because of insufficient financial resources.
The share price will keep going down until dilution stops. That is a Wall Street rule, unless a miracle happens. I am buying again when there is an 8-k filing telling the conversion is finished. Could go to 0.20 dollar/share or less
I fear it'll touch 20cents before going to the dollar. That is what you may get with floorless dilution.
The resignation is bad news. It is a sign that the technology is not working as they hoped for.
Serious question:at which price would you guys start buying?
Thanks, but I my broker doesn't allow me to buy it
I guess this is what will happen:dilution by current conversion, approval for rise in authorised shares to 150million and then dilution from AS by ATM. That's why I will only buy after they can show they have sufficient cash to continue operations for at least 18 months. But I keep my current shares as well in case a miracle might happen.
I have a lot of shares and planning to increase my shares in a couple of months (after new year, in q2/3, after the dilution is gone). Maybe this goes back to .15 or even lower, but the number of outstanding shares will remain low (less than 100 million). That means that with good news (partnerships, phase 2 results, spin off news, ...) the share price will be above the dollar in no time. That can happen today, but probably the share price will sink first.
All I see is the $45/share target from SeeThruequities
Indeed. Look at my sticky post.
NEW$$$$:Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs
http://ih.advfn.com/p.php?pid=nmona&article=69021054&symbol=AMBS